Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
New Day Diagnostics LLC currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active matter is assigned to a distinct examiner and is situated within a single art unit. The concentration of the portfolio in a specific administrative unit suggests a focused review process for the company's current patent applications. Such a structure allows for a direct prosecution strategy without the need to reconcile conflicting feedback from multiple art units.
SALMON, KATHERINE D is identified as the busiest examiner for this portfolio. Because the total volume of pending actions is 1, this examiner handles the entirety of the company's active patent prosecution. The outcome of this matter will be determined by the specific examination standards of the assigned official. Practitioners should focus on the specific procedural history of this examiner to anticipate potential hurdles in the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALMON, KATHERINE D | 1 | 42.9% | +37.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17785302 | METHODS FOR DETECTING COLORECTAL CANCER | SALMON, KATHERINE D | 19d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17785302 | METHODS FOR DETECTING COLORECTAL CANCER | SALMON, KATHERINE D | 19d overdue |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17785302 | METHODS FOR DETECTING COLORECTAL CANCER | SALMON, KATHERINE D | 1682 | §103§112 | Final Rejection | 19d overdue | Pending | Jun 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNew Day Diagnostics LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Katherine D Salmon has the most, with 1 of New Day Diagnostics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.